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Feline calicivirus depends on host-cell proteins for its replication. We previously showed that knockdown
of nucleolin (NCL), a phosphoprotein involved in ribosome biogenesis, resulted in the reduction of FCV
protein synthesis and virus yield. Here, we found that NCL may not be involved in FCV binding and entry
into cells, but it binds to both ends of the FCV genomic RNA, and stimulates its translation in vitro.
AGRO100, an aptamer that speciﬁcally binds and inactivates NCL, caused a strong reduction in FCV
protein synthesis. This effect could be reversed by the addition of full-length NCL but not by a ΔrNCL,
lacking the N-terminal domain. Consistent with this, FCV infection of CrFK cells stably expressingΔrNCL
led to a reduction in virus protein translation. These results suggest that NCL is part of the FCV RNA
translational complex, and that the N-terminal part of the protein is required for efﬁcient FCV replication.
& 2015 Elsevier Inc. All rights reserved.Introduction
Human caliciviruses (HuCVs), from the Norovirus and Sapovirus
genera in the Caliciviridae family, are a major cause of epidemic
gastroenteritis that affects people of all ages (Widdowson et al.,
2005). Despite their impact on public health, information regard-
ing the HuCVs replicative cycle has been limited due to the difﬁ-
culty to grow them in cultured cells (Duizer et al., 2004; Jones
et al., 2014; Taube et al., 2013). Feline calicivirus (FCV), a member
of the genus Vesivirus, can be propagated efﬁciently in conven-
tional cell culture (Kreutz et al., 1994), and has served as an
important model for the study of calicivirus molecular biology
(Papafragkou et al., 2013; Vashist et al., 2009). Similar to other
positive strand RNA viruses, FCV replication involves interactions
of the virus proteins with a number of host cellular factors (Li and
Nagy, 2011; Liu et al., 2009). The junctional adhesion molecule
1 protein (JAM-1) is a functional receptor for FCV virions (Makino
et al., 2006); some eukaryotic translation initiation factors, such asica y Patogénesis Molecular
l IPN Av. IPN 2508. Col. San
l.: þ521 55574738005655;
ez-Escolano).eIF4E, eIF4A, and eIF4G, promote translation of the viral RNA
(Chaudhry et al., 2006; Goodfellow et al., 2005). Moreover, the
polypyrimidine tract-binding protein (PTB) can bind to the 50
terminal end of the FCV genomic and subgenomic RNAs, and is
required for viral replication (Karakasiliotis et al., 2010). It was
suggested that PTB functions as a negative regulator of FCV
translation, promoting the synthesis of RNA (Karakasiliotis et al.,
2010).
Several more studies have reported the identiﬁcation of a
number of host-cell proteins that interact with the 50- and 30- ends
of calicivirus genomes (Gutierrez-Escolano et al., 2000, 2003;
Vashist et al., 2012). However, the functional role of these inter-
actions remains poorly understood. Our previous work showed
that nucleolin (NCL) in vitro associates with the 30 end from the
FCV genomic RNA. The NCL association with the genomic RNA was
further conﬁrmed in infected cells, and a reduction of its expres-
sion by siRNA decreased protein synthesis and viral yield, con-
ﬁrming its role in the FCV life cycle (Cancio-Lonches et al., 2011).
NCL is a multifunctional phosphoprotein with a molecular
weight of 100–110 kDa (Tajrishi et al., 2011). This protein resides
primarily in the cell nucleolus; however it can also be found in the
nucleus, cytoplasm and on the surface of some cells (Borer et al.,
1989; Hovanessian et al., 2000; Losfeld et al., 2011; Tajrishi et al.,
2011). NCL has three well-deﬁned domains. The N-terminal
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Fig. 1. Nucleolin is expressed in the surface of CrFK cells. A) Non-permeabilized and permeabilized CrFK cells with acetone, were stained with an anti-NCL antibody (green),
and visualized by indirect immunoﬂuorescence using Alexa 488 as secondary antibody. DAPI was used for nuclei staining (blue). B) Non-permeabilized CrFK cells were
incubated with anti-NCL (black line) or anti-rabbit IgG antibodies (gray shaded area), used as an isotype control. C) CrFK cells were treated with sulfosuccinimidyl-6- (biotin-
amide) hexanoate (þ) or vehicle () and biotinylated proteins were precipitated with streptavidin-agarose, and separated by SDS-PAGE. NCL and hnRNP A1 proteins were
detected by immunoblotting using speciﬁc anti-NCL and anti-hnRNP A1 antibodies respectively.
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binding rDNA and histone H1, and some ribosomal proteins (Erard
et al., 1988; Ginisty et al., 1998). The central region contains an
RNA-binding domain with four RNA recognition motifs (RRM), and
is responsible for interactions with p53, beta-globin, Hsp90, and
Bcl-XL mRNAs (Abdelmohsen et al., 2011; Jiang et al., 2006; Serin
et al., 1996; Takagi et al., 2005; Wang et al., 2011; Zhang et al.,
2008). The NCL C-terminal region contains the glycine-arginine-
rich (GAR) domain that is essential for binding of ribosomal pro-
teins and the telomerase RNA subunit hTERT (Bouvet et al., 1998;
Khurts et al., 2004).
NCL controls a wide range of fundamental cellular processes
such as ribosome biogenesis, proliferation and cellular cycle reg-
ulation (Cong et al., 2012; Ginisty et al., 1998; Ugrinova et al.,
2007). On the cell surface, NCL serves as a receptor for ligands such
as lactoferrin (Legrand et al., 2004), midkine protein (MK) (Take et
al., 1994), pleiotrophin (PTN) (Said et al., 2005), and AGRO100, an
oligonucleotide aptamer that has been shown to bind with high
speciﬁcity and afﬁnity to the NCL RRMs (Bates et al., 2009; Dahl et
al., 1987; Mongelard and Bouvet, 2010; Reyes-Reyes et al., 2010;
Soundararajan et al., 2009; Xu et al., 2001). The cell surface-
expressed NCL is required for the efﬁcient entry of human para-
inﬂuenza virus type 3 (HPV 3) into human lung epithelial A549
cells (Bose et al., 2004). NCL has been also identiﬁed as a receptor
for the human respiratory syncytial virus (RSV) (Tayyari et al.,
2011), and has been implicated as a low afﬁnity receptor for the
human immunodeﬁciency virus (HIV) (Said et al., 2002). The
cytoplasmic NCL has been reported to interact with several viral
proteins, such as hepatitis C virus (HCV) nonstructural protein 5B
(NS5B), (Bouvet et al., 1998; Hirano et al., 2003; Kusakawa et al.,
2007). Recently, it was shown that NCL could interact with dengue
virus (DV) capsid protein, suggesting its role in viral morphogen-
esis (Balinsky et al., 2013).In addition to protein–protein interactions, NCL has been
shown to bind viral RNAs, such as the 50 end of the HCV, poliovirus
(PV), and rhinovirus (HRV) genomic RNAs (Lu et al., 2004). NCL
interaction with the untranslated regions (UTRs) of the PV and
HRV genomic RNAs has been found to stimulate translation of viral
proteins (Izumi et al., 2001; Waggoner and Sarnow, 1998). On the
other hand, NCL (Nsr1p in yeast), bound to the 30 UTR of the
tombusvirus (TBVS) RNA has been shown to inhibit its replication
by interfering with recruitment of the viral RNA for replication
(Jiang et al., 2010).
Due to the different processes that NCL modulates during viral
replication, and because in our previous studies we demonstrated
the requirement of NCL for an efﬁcient FCV viral production
(Cancio-Lonches et al., 2011), we wanted to investigate the speciﬁc
function of this cellular protein during the different steps of the
FCV replicative cycle. In the present report, we examined a role of
NCL in binding and entry of FCV into the CrFK cells. We demon-
strated that NCL speciﬁcally binds to the 50 and 30 end of the FCV
genomic RNA, and stimulates its translation in vitro. We also
showed that NCL mutants lacking the amino terminal domain (but
containing RRMs) inhibit FCV RNA translation in vitro, and reduce
viral protein synthesis and viral production during infection.Results
Detection of NCL on the surface of CrFK cells
We previously reported that NCL associates with the FCV 30
UTR and is required for an efﬁcient viral replication cycle (Cancio-
Lonches et al., 2011), since knockdown in CrFK cells by siRNAs
caused a reduction in FCV production. To establish the speciﬁc role
of NCL in the FCV replicative cycle, we analyzed ﬁrst its possible
role in virus binding and entry. It has been reported that JAM-1
B.A. Hernández et al. / Virology 489 (2016) 51–62 53serves as a functional receptor for some strains of FCV (Makino et
al., 2006). The expression of this protein is not sufﬁcient for pro-
ductive infection by some FCV isolates (Ossiboff and Parker, 2007),
suggesting that additional receptors or co-receptors may be pre-
sent on permissive cells. To determine if NCL could have a role in
FCV binding and entry, it was necessary to determine if NCL was
present on the surface of CrFK cells. Non-permeabilized and per-
meabilized CrFK cells were incubated with speciﬁc anti-NCL
antibody (H-250, Santa Cruz Biotechnology) and NCL subcellular
localization was detected by immunoﬂuorescence. NCL was pre-
dominantly localized in the nucleoli of permeabilized CrFK cells
(Fig. 1A, upper panel), while, in non-permeabilized cells, NCL was
detected predominantly on the surface (Fig. 1A, lower panel). The
presence of NCL was also detected on the surface of non-
permeabilized CrFK cells by ﬂow cytometry using the same anti-
body described above (Fig. 1B). Non-permeabilized CrFK cells were
incubated with an anti-NCL (black line) or an anti-rabbit IgG
antibody (gray shaded area) as an isotype control. In the repre-
sentative histogram, the ﬂuorescence intensity of CrFK cells
labeled with anti-NCL antibody (black line) shifted from the basal
ﬂuorescence of cells incubated with the isotype control antibody
(gray). Approximately 32% of the analyzed cells showed the pre-
sence of the NCL protein on their surface (Fig. 2B). To detect the
presence of cell-surface NCL biochemically, the surface proteins of
CrFK cells were biotinylated (Fig. 1C, þ) or not (Fig. 1C, ) with a
cell-impermeable biotinylation reagent. The biotinylated proteins
were isolated by absorption to streptavidin-agarose beads and
subjected to immunoblotting by anti-NCL and anti-heterogeneous
nuclear ribonucleoprotein (hnRNP) A1 antibodies. Detection of the
110-kDa NCL-speciﬁc protein band among the streptavidin-
precipitated biotinylated proteins was consistent with the pre-
sence of NCL on the surface of CrFK cells (Fig. 1C). hnRNP A1, a
protein present in the cytoplasm and predominantly in the
nucleus, served as a control for the cell surface labeling: it was not
detected in the streptavidin-bound plasma membrane fraction
(Fig. 1C).
Antibodies against NCL did not inhibit FCV-binding to CrFK cells
surface
To investigate whether NCL on the CrFK cells surface is involved
in FCV binding, NCL was blocked with anti-NCL antibody prior to%
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Fig. 2. Anti-NCL antibody does not inhibit FCV binding to CrFK cells. A) Non-treated (bla
(blue line), and anti-rabbit IgG (red line) antibodies, or with the JAM-1 preimmune seru
present on the cell surface were detected by ﬂow cytometry using a commercial anti-F
binding inhibition as measured by mean ﬂuorescence intensity. The error bars represen
(**) are indicated.virus infection, and FCV presence on the cell surface was tested by
ﬂow cytometry (Fig. 2). Pre-incubation of cells with anti-NCL
antibody (40 μg/ml) did not inhibit FCV binding to the cell sur-
face (Fig. 2A, blue line), in contrast, pre-incubation of cells with a
1:5 dilution of an anti-JAM1 guinea antibody partially (50%)
inhibited FCV binding to CrFK cells (Fig. 2A, pink line). Untreated
cells or cells that were pre-incubated with JAM1 pre-immune
serum (1:5 dilution) or with anti-rabbit IgG antibodies (40 μg/ml),
did not show inhibition of FCV binding (Fig. 2A, blue light, green
and red lines respectively). The data from three independent
binding experiments are summarized in Fig. 2B.Antibodies against NCL and FL rNCL soluble protein did not inhibit
FCV plaque formation in CrFK cells
Even though anti-NCL antibody did not interfere with FCV
binding to CrFK cells, it was important to test whether it has any
capacity to offset the development of the FCV CPE and infection
(Fig. 3). Pre-incubation of CrFK cells with a 1:5 dilution of JAM-1
antibody, signiﬁcantly reduced the ability of FCV to produce CPE
(Fig. 3A). In contrast, pre-incubation of cells with a 40 μg/ml
dilution of anti-NCL antibody (Fig. 3A) did not inhibit CPE pro-
duced by FCV infection. As expected, anti-rabbit IgG (40 μg/ml)
and JAM1 pre-immune serum (1:5 dilution) used as negative
controls, had no substantial effect on the CPE produced by FCV.
Virus titration analysis of collected cell supernatants showed that
only CrFK cells pretreated with anti-JAM 1 antiserum had a
reduced level of virus production (Fig. 3B). Virus infection of cells
pretreated with anti-NCL antibody resulted in a level of virus
ampliﬁcation similar to that in untreated cells or in cells pre-
treated with anti-rabbit IgG antibody, or JAM1 pre-immune serum
(Fig. 3B).
On the other hand, FCV pretreated with FL rNCL (OriGene) or
BSA (bovine serum albumin) did not affect virus infection (Fig. 3C).
However, CrFK cells treated with the mix of FL rNCL and the NCL
ligand AGRO100 coupled to a FITC molecule (FITC-AGRO100)
reduced its ability to bind to CrFK cells (Fig. 3D). Taken together,
these results strongly suggest that FL rNCL soluble protein does
not inhibit FCV infection of CrFK cells.ck and blue light lanes), and CrFK cells treated with anti-JAM-1 (pink line), anti-NCL
m (green lanes), were incubated or no (black line) with FCV particles. FCV particles
CV antibody (Santa Cruz Biotechnology). B) The bar chart illustrates the amount of
t the standard deviations from three independent experiments. Values of Po0.001
-JAM1 antibody
-NCL antibody
-rabbit IgG-antibody JAM1 Preimmune serum
No antibodynon-infected
FLrNCL 332
rGST 406
No protein           415
F I T C -
A G R O 1 0 0
MFI
α α
α
Fig. 3. Anti-NCL antibody an FL NCL soluble protein does not have an effect on FCV infection in CrFK cells. A) Non-treated and CrFK cells treated for 1 h at 37 °C with anti-
NCL, anti-rabbit IgG, anti-JAM-1 antibodies, and JAM-1 preimmune serum, were non-infected or infected with FCV at an MOI of 0.01 for 24 h. Cytopathic effect was observed
by phase contrast microscopy. B) The bar chart illustrates the virus yield in supernatants determined by plaque assay. Error bars represent the standard deviations from three
independent experiments. Value of Pr0.05 (*) is indicated. C) Pre-incubated FCV (0.01 MOI) with BSA or FL rNCL proteins were added or not (no treatment) to CrFK cells for
24 h, and virus yield was determined in the supernatants by plaque assay. D) CrFK cells treated for 45 min on ice with AGRO-100 (gray shaded area) or a mix of 1 μM FL rNCL
(dashed line) or rGST (black line) proteins pre-incubated with 5 μM FITC-AGRO for 2 h at 4 °C. Mean ﬂuorescence intensity (MFI) of FITC-AGRO100 was analyzed by ﬂow
cytometry.
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Since antibody-blocking experiments showed that administra-
tion of anti-NCL-speciﬁc antibody prior to FCV infection had no
effect on the virus binding and entry, we examined a possible role
of NCL in subsequent steps of the virus replication cycle such astranslation and replication of the virus RNA. The terminal ends of
viral genomes contain important sequences and structural ele-
ments that are recognized by cellular proteins and are critical for
translation and RNA replication (Ahlquist et al., 2003). NCL is
known to play a regulatory role during translation and replication
of several viruses (Izumi et al., 2001; Jiang et al., 2010).
III
rGST ( g)
rNCL ( g)
3’UTR -UTP [ P] 
-
-
+
-
4.0
+
-
5.0
+
5.0
-
+
1  2  3  4 5
-
3.0
+
rGST ( g)
rNCL ( g)
5’TR -UTP [ P] 
-
-
+
-
2.0
+
-
3.0
+
3.0
-
+
-
1.0
+
1 2  3  4  5
I
II
RBD1 RBD2 RBD4RBD3 GARGST or GFP
N-ter domain
RBD1 RBD2 RBD4RBD3 GAR
Central domain C-ter domain
FL-NCL
rNCL
Nuclear localization signal
RBD RNA binding domain
GAR GAR domain
N glycosylation sites
Fig. 4. NCL recombinant protein binds to 50 terminal region and 30 UTR from the FCV genomic RNA. A) Schematic representation of NCL and ΔrNCL proteins. The RNA binding
domains (RBD), nuclear localization signal (NLS), and the GAR domain are highlighted. N-glycosylation sites, located at positions 317–319, 399–401, 403–405, 477–479, and
491–493 are indicated. GST or GFP are located in the N-terminal end of the ΔrNCL protein. B) The [α-32P] UTP-labeled RNAs corresponding to the 50 terminal region or C) the
30 UTR of the FCV genomic RNA, were interacted with increasing amounts of ΔrNCL, (lanes 2, 3 and 4 respectively), or with the rGST protein (lanes 5). Lanes 1: free RNA.
Migration of complexes is indicated.
B.A. Hernández et al. / Virology 489 (2016) 51–62 55Interestingly, NCL forms an RNP complex with the 30UTR of the
FCV RNA (Cancio-Lonches et al., 2011); then, to determine if NCL
can directly bind to the 50 end and the 30 UTR from the FCV
genomic RNA, a recombinant NCL was produced. To date it has not
been possible to express full-length NCL, most probably due to the
propensity of the N-terminal highly acidic domain to cause NCL
auto-proteolysis (Chen et al., 1991; Izumi et al., 2001; Srivastava et
al., 1989; Valdez et al., 1995); thus, a truncated form of NCL,
ΔrNCL, that contain the protein central and C-terminal parts with
four RNA recognition motifs (RRM) was expressed and puriﬁed
(Fig. 4A). When in vitro synthesized RNAs containing the ﬁrst 260
nt from the 50 TR and 50 nt from the 30 UTR of FCV genomic RNA
were incubated with the ΔrNCL, the protein formed RNA–protein
complexes that could be visualized by EMSA. ΔrNCL was able to
speciﬁcally bind to the 50 TR of the FCV RNA, forming two com-
plexes (Fig. 4A). Moreover, ΔrNCL was also able to interact with
the FCV 30 UTR, and form a complex (II), which is enriched with
increasing amounts of ΔrNCL (I) (Fig. 4B). No complex formation
was observed when rGST was incubated with any of the FCV RNAs
(Fig. 4A and B). These results indicate that ΔrNCL binds directly to
the 50 TR and the 30 UTR of the FCV RNA.
NCL is required for an efﬁcient FCV in vitro translation
Because NCL could speciﬁcally bind both ends of the FCV
genomic RNA, we investigated a possible role of this protein in
regulating viral RNA translation. The effect of NCL on translationwas analyzed using a rabbit reticulocyte lysate (RRL) system,
which has been reported to support FCV RNA translation (Good-
fellow et al., 2005; Karakasiliotis et al., 2010). The presence of NCL
in these lysates could be readily detected by Western blot, using
anti-NCL antibody (kindly donated by Kurt Gustin, University of
Arizona, Phoenix) (Fig. 5A). The virus RNAwas translated in vitro in
the presence of the NCL functional inhibitor AGRO100. The in vitro
translation assay showed that increasing amounts of AGRO100
included in the RRL resulted in an inhibition of FCV RNA transla-
tion that was dose-dependent (Fig. 5B and C). In contrast, the
inclusion of a non-speciﬁc oligonucleotide (oligo-dT) in the RRL,
did not affect FCV translation (Fig. 5B, lane 7 and C), suggesting
that inactivation of NCL by AGRO100 was responsible for the
inhibition of viral protein synthesis.
ΔrNCL binds speciﬁcally to AGRO100
To determine if AGRO100 binds to NCL, FITC-AGRO100 was
incubated with the ΔrNCL, and the complex formation was ana-
lyzed by EMSA (Fig. 6). Two complexes were formed in the pre-
sence of 1 μg of ΔrNCL, and gradual increase in intensity of both
bands was observed when FITC-AGRO100 was incubated with
increasing amounts of ΔrNCL (Fig. 6A, lanes 2–6). In contrast, no
complex formation was observed when rGST was added to the
reaction (Fig. 6A, lane 7), suggesting that the interaction between
AGRO100 and ΔrNCL was speciﬁc. To further conﬁrm the speciﬁ-
city of the interaction between AGRO-FITC and ΔrNCL, the
0
0.2
0.4
0.6
0.8
1
1.2
Ctrol 
(+)
2.5 5 7.5 10 15 Ctrol 
(-)
R
el
at
iv
e 
va
lu
e
AGRO100 ( M)
Oligo dT (μg)
AGRO100 (μg)
FCV RNA
-
-
+
-
0.2
+
-
0.4
+
-
0.8
+
-
1.6
+
-
3.3
+
3.3
-
+
-
-
-
1  2  3  4 5   6  7 8 
WB anti-NCL
RRL
rNCL
CrFK total extracts
-
+
-
-
-
+
+
-
-
100 –
75 –
p32 
p39 
VP1 
μ
•
•
•
Fig. 5. AGRO100 inhibits FCV in vitro translation. A) Total extracts from CrFK cells, ΔrNCL and extracts from RRL (lanes 1, 2 and 3 respectively) were analyzed by SDS-PAGE
and NCL was detected by western blot using a speciﬁc monoclonal antibody. B) FCV in vitro translation was performed in RRL extracts and the 35S methionine labeled viral
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or oligo-dT molecules (Fig. 6B). The addition of 30x and 60x of
AGRO100 (non-coupled to FITC), strongly reduced complex for-
mation with ΔrNCL, while the addition of the same amount of
oligo-dT did not affect complex formation (Fig. 6B, lanes 3–4 and
5–6, respectively), indicating that AGRO100 speciﬁcally binds
to ΔrNCL.
NCL enhances FCV RNA in vitro translation and blocks the AGRO100
inhibitory effect
To determine if FL rNCL and ΔrNCL have the ability to rescue
FCV protein synthesis lost by the presence of AGRO100, these
proteins were included into the reactions containing inhibitory
levels of AGRO100 (Fig. 7A and B). The inclusion of 1.4 and 2.0 μg
of FL rNCL restored in vitro translation of FCV inhibited byAGRO100 (Fig. 7A, lanes 3 and 4 respectively), however, the same
amount of ΔrNCL (Fig. 7B, lanes 3 and 4) or 2.0 μg rGST (Fig. 7A,
lane 5) failed to restore FCV in vitro translation. A possible expla-
nation for this might be that the N-terminal end of the NCL protein
is required for the stimulatory/translational activity of this protein.
Consistent with that, deletion of the N-terminus inΔrNCL resulted
in failure of the truncated version of NCL to reduce the AGRO100
inhibitory effect.
The addition of increasing amounts ofΔrNCL to the FCV in vitro
translation reaction strongly reduced FCV viral protein synthesis
(Fig. 7C, lanes 2–4). In contrast, when increasing amounts of FL
rNCL were added, FCV protein synthesis was enhanced in a dose-
dependent manner (Fig. 7D, lanes 2–4), conﬁrming that FL rNCL is
a positive regulator of FCV in vitro translation. Parallel experiments
were carried out to determine the effect of ΔrNCL and FL rNCL in
cap-dependent translation. The addition of increasing amounts of
Fig. 7. Full length NCL but not the recombinant NCL positively regulates FCV in vitro translation. FCV in vitro translation was performed in RRL extracts and the 35S
methionine labeled viral proteins were analyzed by SDS-PAGE. A) in the presence of 0.8 μg of AGRO100 (lanes 2–5), and increasing concentrations of FL rNCL (lanes 3 and 4);
B) in the presence of 0.3 μg of AGRO100 (lanes 2–6) and increasing concentrations of ΔrNCL (lanes 3 and 6); C) in the presence of increasing amounts of ΔrNCL (lanes 2–4);
and D) in the presence of increasing amounts of FL rNCL (lanes 2–4). E) Non-viral capped RNA (GFP) in the presence of increasing concentrations of ΔrNCL (lanes 2–4); and F)
in the presence of increasing amounts of FL rNCL (lanes 2–4). Lanes 1: FCV or GFP in vitro translation. Reactions performed in the presence of rGST or in the absence of FCV or
Cap-RNAs are indicated.
B.A. Hernández et al. / Virology 489 (2016) 51–62 57ΔrNCL to the capped-GFP RNA in vitro translation reaction caused
a reduction of the protein synthesis (Fig. 7E, lanes 2–4), while
increasing amounts of FL rNCL promoted protein synthesis in a
dose-dependent manner (Fig. 7E, lanes 2–4). Similar results were
obtained with capped-Hsp70 RNA (data not shown). Since NCL is
also required for PV and human rhinovirus (HRV) IRES dependent
translation (Izumi et al., 2001), it is possible that this protein could
be a general positive regulator in the RRL in vitro translation
system.
The inability of the ΔrNCL to restore FCV in vitro translation
inhibition by AGRO100, as well as its capacity to inhibit FCV viral
protein synthesis suggests that this protein could have a negative
regulatory effect in FCV translation.
NCL N-terminal end is required for the FCV protein synthesis and an
efﬁcient viral production
To further verify the dominant-negative effect of the ΔNCL on
FCV infection, a CrFK cell line that stably expresses GFP-ΔrNCLwas generated (Fig. 8A). Analysis of epiﬂuorescence images of
CrFK-GFP-ΔrNCL cells revealed a cytoplasmic and nucleolar pre-
sence of the GFP-ΔrNCL (Fig. 8, right panel). In contrast, GFP
transfected cells showed a uniform GFP distribution throughout
the cell (Fig. 8A, left panel). To verify the GFP-ΔrNCL expression,
total cell lysates derived from non-transfected (NT), GFP- and GFP-
ΔrNCL-transfected cells were analyzed by western blot using the
speciﬁc anti-NCL antibody (Fig. 8B). The presence of the 110-kDa-
protein band corresponding to the endogenous NCL was observed
in all samples tested (Fig. 8B, lanes 1–6). However, the presence of
a 70 kDa protein corresponding to the GFP-ΔrNCL fusion protein
was only observed in the GFP-ΔrNCL transfected cells (Fig. 8B,
lane 3 and 6), as expected.
After having determined the stable expression of GFP-ΔrNCL by
microscopy and western blot (Fig. 8A and B), non-transfected as well
as transfected cell lines were infected with FCV at an MOI of 5, and
the production of NS3 protein was analyzed at 5 hpi (Fig. 8B and C).
The non-transfected as well as the GFP-transfected cells infected
with FCV, showed equivalent amounts of NS3 expression (Fig. 8B,
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Fig. 8. FCV protein synthesis and virus production in CrFK cells expressing ΔrNCL. A) CrFK cells were transfected with the empty vector (GFP) or pEGFP–C1-ΔNCL (GFP-
ΔrNCL 302-707 aa) plasmids. GFP or GFP-ΔrNCL G418-resistant cells were selected using ﬂuorescence microscopy. (B) Non-transfected (NT), and GFP and GFP-ΔrNCL
transfected CrFK cells were mock-infected (NI) (lanes 1, 2, and 3) or infected (INF) (lanes 4, 5, and 6) with FCV at MOI of 5. Protein lysates were obtained after 5 hpi and the
presence of NCL and NS3 was determined by Western blot using speciﬁc anti-NCL and anti-NS3 antibodies. Actin was used as the loading control. C) NS3 band intensities
were quantiﬁed by densitometry analysis using ImageJ software and are expressed as the relative value in relation to the actin expression level. Error bars represent the
standard deviation from three independent experiments. Value of Po0.01 (**) is indicated. D) The bar chart illustrates the virus yield in supernatants of CrFK cells
transfected with GFP and GFP-ΔrNCL, quantiﬁed by plaque assay. Error bars represent the standard deviations from three independent experiments.
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ΔrNCL showed a reduced amount of NS3 protein (Fig. 8B, lane 6, and
C), suggesting that the amino-terminal end of the NCL was required
for an efﬁcient production of viral proteins in culture cells. It was
also possible that GFP-ΔrNCL behaves as a dominant-negative
mutant for NCL, and thus block or reduce the synthesis of NCL-
dependent cellular proteins required for FCV RNA translation. Then,
in vitro translation assays of CrFK cells transfected with GFP or GFP-
ΔrNCL in the presence of 35S-Met were performed, and the protein
synthesis proﬁle was compared (Supplementary Fig. 1). The amount
of the labeled bands was similar under both conditions, suggesting
that GFP-ΔrNCL does not affect the synthesis of other cellular
proteins.
Finally, the titers of virus produced from the cells transfected
with GFP or GFP-ΔrNCL were determined (Fig. 8D); Signiﬁcantly
lower (two-log reduction) virus titers than those obtained from
cells transfected with GFP were observed for CrFK-GFP-ΔNCL cells
(Fig. 8D), suggesting that the expression of the NCL deletion
mutant was responsible for the reduction of viral production. The
result could be the consequence of a direct interaction of the non-
functional ΔNCL bound to the FCV RNA, acting as a negative
dominant and thus, interfering with the interaction of the com-
plete and functional NCL.
Discussion
As obligate intracellular parasites, viruses rely on cellular
pathways and processes for almost all phases of their life cycle(Ahlquist et al., 2003; Lin et al., 2009). In our previous report
(Cancio-Lonches et al., 2011), we identiﬁed NCL as a host cell factor
present in RNP complexes formed with both Norwalk virus (NV)
and FCV RNAs. Moreover, we showed that siRNA knockdown of
NCL in CrFK cells, caused a reduction in cytopathic effect and in
FCV production, conﬁrming a requirement for NCL in some aspect
(s) of the FCV life cycle (Cancio-Lonches et al., 2011). The purpose
of our present study was to investigate a potential mechanism for
the function of NCL in FCV replication.
We ﬁrst examined a possible role for NCL as a receptor or
attachment ligand during virus binding and entry. The JAM-1
protein (Makino et al., 2006) and sialic acid α2,6 (Stuart and
Brown, 2007) have been implicated in early entry events for a
number of FCV strains, but NCL had not been investigated. We
demonstrated for the ﬁrst time that NCL is expressed on permis-
sive CrFK cells. However, pretreatment of CrFK cells with anti-NCL
speciﬁc antibody, did not affect FCV binding and infection. More-
over, FL rNCL prevented the binding of the NCL ligand FITC-AGRO
to CrFK cells, but not the binding of FCV. These ﬁndings suggest
that NCL may not participate in early stages of the FCV life cycle,
but rather is involved in post-entry stages of infection.
Our previous studies showed that NCL was part of an RNP
complex formed with the FCV genomic RNA (Cancio-Lonches et al.,
2011); however, a direct interaction with either the 50 TR or the 30
UTR had not been demonstrated. The binding of NCL to both
terminal regions of the FCV genome, and the correlation of its
knockdown by siRNA to a reduction in NS viral protein synthesis
(Cancio-Lonches et al., 2011), suggest a role in viral RNA
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RNA virus genomes have processes inherently linked, both as a
template for replication by the RNA polymerase and as a template
for translation; thus, we studied the role of NCL in viral protein
synthesis in the absence of viral RNA replication using RRL (Kar-
akasiliotis et al., 2010). Calicivirus translation in RRL has been
previously demonstrated (Goodfellow et al., 2005; Karakasiliotis et
al., 2010), thus, the presence of NCL in these lysates, reported here
and by others (Chen et al., 2012a), suggested that this protein
might have a role in FCV translation. Three observations supported
a role for NCL in translation. First, the NCL-speciﬁc ligand
AGRO100 inhibited FCV RNA translation in a dose-dependent
manner. Second, translation efﬁciency could be rescued by the
addition of intact FL rNCL. Finally, FL rNCL could enhance trans-
lation when added to RRL in a dose dependent manner. Taken
together, intact FL rNCL was linked to efﬁcient translation in this
in vitro translation assay.
Our next series of experiments examined the location of the
domain in the NCL protein responsible for the enhancement of
translation. We engineered a truncated protein construct desig-
nated ΔrNCL that lacked the N-terminal domain involved in
nuclear localization and binding to a number of ribosomal pro-
teins, but that retained the central RNA binding domains and the
C-terminal ribosome binding domain. This truncated protein was
unable to restore translation efﬁciency in the presence of
AGRO100. Furthermore, its presence inhibited the translation of
viral RNA in RRLs. Cells stably expressing this truncated form of
NCL showed reduced viral protein synthesis and decreased virus
yields (2 log reduction in titer). Taken together, these results
strongly suggest that the ΔrNCL acts as a negative regulator,
possibly competing out binding of endogenous NCL to FCV RNA. In
support of this hypothesis, the FL NCL has been reported to sti-
mulate the PV IRES-mediated translation in vitro, while NCL
mutants containing the C-terminal RNA binding domains but
lacking the N-terminal domain were found to inhibit in vitro
translation of the same RNA. The translation inhibitory activity of
these mutants correlates with their ability to bind the 50 UTR
sequence (Izumi et al., 2001). On the other hand, the lack of the N-
terminal domain of ΔrNCL may prevent protein interactions with
NCL that might be required for its function (Bouvet et al., 1998;
Erard et al., 1988; Ginisty et al., 1998; Sicard et al., 1998). Here, we
demonstrate that NCL has a role in FCV VPg-mediated translation
in vitro; however, due to the fact that ΔrNCL also inhibited cap-
dependent synthesis of GFP and Hsp70 in RRL, and that the
addition of FL rNCL enhances their translation in a dose dependent
manner, it is quite possible that NCL could act as a general trans-
lation factor, by its ability to bind a variety of mRNAs, as previously
suggested (Izumi et al., 2001).
NCL has the capacity to bind G-rich elements located in both
coding and noncoding sequences of several cellular mRNAs that
encode cell growth- and cancer related proteins, and enhances
their translation (Abdelmohsen et al., 2011). In some cases, NCL
promotes mRNA translation without inﬂuencing mRNA stability
(Abdelmohsen et al., 2011), while in others, it can differentially
regulate both RNA and protein levels (Woo et al., 2013). NCL has
the ability to bind to the 50 and 30 UTRs of several cellular mRNAs;
when binding to the 30UTR of the cytokine CSF-1 mRNA, promotes
deadenylation and decay of CSF-1. On the other hand, its interac-
tion with the poly A binding protein (PABP) C, promotes the for-
mation of the mRNP closed loop, and enhances CSF-1 protein
levels (Woo et al., 2013). NCL is one of the protein factors which
participates in the circularization of the α1 (I) collagen mRNA in a
50 stem-loop dependent manner; it has been proposed that NCL
stabilizes the mRNA and relaxes the secondary structure of the 50
stem-loop, through its RNA helicase activity, thus, making the start
codon accessible to ribosomes. The ribosomal protein L26 (RPL26)and NCL are involved in the translational control of p53. In
unstressed cells, NCL repression of p53 translation occurs by its
binding to an intrinsic double-stranded RNA formed by base
pairing between the 50–30-UTR interaction region of human p53
mRNA. NCL RNA binding domains (RBD) are responsible for their
own dimerization/oligomerization, and for the stabilization of the
nucleic acid hybrid structure within the p53 mRNA. After DNA
damage, the RBD of NCL recruits RPL26 to the same interaction
regions of the human p53 mRNA, disrupting the NCL homodimer
by forming a heterodimer that facilitates translation of p53 mRNA.
Thus, disruption of NCL–NCL homodimer by RPL26 may be the
switch between translational repression and activation after stress
(Chen et al., 2012b).
Then, the regulation of translation by NCL in several cases is
determined by the protein ability to interact with both ends of the
mRNA, and is often involved in the circularization of its target
RNA, alone, or as a part of a protein complex. Circularization of the
cellular mRNAs has been involved as a strategy for a more efﬁcient
protein synthesis; however, for viral genomic RNAs, the 50–30 end
interactions are also implicated in the regulation of RNA replica-
tion (Alvarez et al., 2005; Herold and Andino, 2001; Nicholson and
White, 2014). Since our previously published data report that NCL
forms a RNP complex with the 30UTR and with NS6/7, and here, we
demonstrated the direct interaction of NCL with both the 50 and
the 30 UTR from the FCV genomic RNA, it is possible that its role as
a positive regulator of FCV translation, may involve the circular-
ization of the FCV genomic RNA. In this regard, evidence of the 50–
30 end interactions in other caliciviruses such as NV and murine
norovirus (MNV) (Lopez-Manriquez et al., 2013; Sandoval-Jaime
and Gutierrez-Escolano, 2009), require an RNA–RNA interaction
that is further stabilized by cellular proteins, and NCL could be one
of the candidates for this function. On the other hand, we cannot
rule out the possibility that NCL may also be involved in the reg-
ulation of other steps during the FCV replicative cycle, such as RNA
replication.Materials and methods
Cell culture and virus
CrFK cells obtained from the American Type Culture Collection
(ATCC) (Rockville, MD) were grown in Eagle's minimal essential
medium with Earle's balanced salt solution and 2 mM L-glutamine
that was modiﬁed by the ATCC to contain 1.0 mM sodium pyr-
uvate, 0.1 mM nonessential amino acids, 1.5 g/l sodium bicarbo-
nate. The mediumwas supplemented with 10% bovine fetal serum,
5000 U of penicillin and 5 μg/ml of streptomycin. Cells were
grown in a 5% CO2 incubator at 37 °C. In this study, CrFK cells were
infected with the FCV F9 strain American Type Culture Collection
(ATCC) (Rockville, MD). Virus titer was determined by plaque assay
as reported (Escobar-Herrera et al., 2007).
Immunoﬂuorescence assays
CrFK cells (1.5105) were seeded in a 6-well plate containing
glass coverslips pretreated with poly-L-lysine (0.1%) and grown
overnight. The cells were washed once with cold phosphate buffer
(PBS) and treated for 15 min with 2% paraformaldehyde in PBS at
4 °C. Samples were permeabilized with acetone 100%, washed
three times with cold PBS for 5 min and blocked with anti-goat
sera at 5%, for 30 min, at 4 °C. Then, cells were washed one time
with cold PBS for 1 min and incubated with 8 μg/ml of an anti-NCL
antibody (H-250, Santa Cruz Biotechnology) diluted in 5% goat sera
at 4 °C overnight. The samples were washed three times with cold
PBS for 10 min and incubated with the corresponding secondary
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temperature (RT). The samples were washed three times with PBS
and incubated with 1 μg/ml of 40, 6-diamidino-2-phenylindole
dihydrochloride (DAPI) for 10 min. Following the DAPI staining,
the coverslips were washed two times with cold PBS, and mounted
onto glass slides using Vecta-Shield liquid mounting media (Vector
Laboratories A. C.). The images were captured using a TCS SP8
Leica confocal microscope.
Cell surface biotinylation
Biotinylation of the CrFK cells surface proteins was performed
as described previously with some modiﬁcations (Hirano et al.,
2005; Soundararajan et al., 2009). A monolayer of CrFK cells
(1107 cells) was washed with cold PBS, that contained 0.1 mM
Ca2þ and 1 mM Mg2þ(PBSþ), and incubated with 1 mg/ml sul-
fosuccinimidyl-6- (biotin-amide) hexanoate in PBS (Pierce) at 4 °C
for 2 h with gentle agitation. Then, unreacted biotin was quenched
by incubating the treated cells in PBS-100 mM glycine for 2 min at
4 °C. Cells treated without the biotinylation reagent served as a
negative control. After the cells were washed with PBSþ , they
were lysed with a buffer containing 1% Triton X-100, 0.05% sodium
deoxycholate, 5 mm EDTA, 30 mm Tris–HCl (pH 7.4), 150 mm NaCl,
protease inhibitor (complete mini Roche) and 10% glycerol. The
lysates were centrifuged for 5 min at 15,000g. To isolate biotiny-
lated proteins, the supernatants containing 3 mg of a protein were
applied to 1 ml of streptavidin-agarose (Pierce) pre-equilibrated
with lysis buffer and were incubated overnight at 4 °C with gentle
agitation. The matrices were thoroughly washed with lysis buffer,
and bound proteins were solubilized with SDS-PAGE sample buffer
(50 mM Tris–HCl (pH 6.8), 2% SDS, 6% glycerol, 0.1 M dithiothreitol,
1 mM phenylmethylsulfonyl ﬂuoride, 0.015% bromophenol blue) at
95 °C for 5 min and subjected to SDS-PAGE (10% gel). Immuno-
blotting for the detection of NCL was performed using anti-NCL,
and anti-hnRNP A1 antibodies (sc-32301, Santa Cruz Biotechnol-
ogy) were used as a control of non-membranous fraction. Proteins
were visualized by chemiluminescence using SuperSignal™ West
Femto Maximum Sensitivity Substrate (Thermo Scientiﬁc™).
Detection of NCL on CrFK cells surface by ﬂow cytometry
CrFK cells were dispersed with 0.02% EDTA in PBS. 1106 cells
were washed once in ﬂow cytometry buffer (FCB) containing PBS-
BSA 2% and 0.1% NaN3 and incubated with anti-NCL antibody for
1 h at 4 °C. The cells were washed three times with FCB and
incubated with the corresponding secondary antibody (Invitrogen)
for 1 h at 4 °C. The cells were washed three times with FCB and
resuspended in 4% formaldehyde-FCB. The samples were analyzed
with a FACSCalibur (Becton Dickinson, Franklin Lakes, MN).
Virus-binding assay by ﬂow cytometry
Virus-binding assay was performed using a method previously
described (Makino et al., 2006). CrFK cells (1106) were washed
once in FCB and incubated with 3105 FCV particles, for 30 min at
4 °C. For blocking experiments, cells were incubated with anti-
JAM-1 pre- and post-immune sera (1:1), anti-NCL (40 μg/ml), or
anti-rabbit IgG (40 μg/ml) antibodies for 1 h at 4 °C, before the
virus was added. After that, the samples were washed twice with
FCB and incubated with anti-FCV antibody (FCV1-43, Santa Cruz
Biotechnology), that recognizes an epitope on the capsid protein,
for 1 h at 4 °C. Then, the samples were washed three times with
FCB and incubated with the corresponding secondary antibody for
1 h at 4 °C. The cells were washed three times with FCB and
analyzed with a FACSCalibur (Becton Dickinson, Franklin Lakes,
MN). For binding assays, CrFK cells were grown in 175-cm2 ﬂasksand infected with FCV virus; the supernatant was harvested at 24-
h post-infection (hpi), layered onto a 25% sucrose cushion, and
centrifuged at 120,000g for 2 h at 4 °C. The pellet was resuspended
in PBS. The suspension was centrifuged at 650g to remove inso-
luble matter and used for binding assays.
Inhibition experiments
CrFK cells were plated in 96-well plates (1.5104 cells per
well) and allowed to grow for 24 h at 37 °C before being washed
once with cold PBS. Washed cells were incubated with anti-JAM-1
preimmune serum (2.4 μg/μl) (1:5), anti-JAM-1 (2.4 μg/μl) (1:5),
anti-NCL (40 μg/ml) or anti-rabbit IgG (40 μg/ml) antibodies for
1 h at 37 °C. After antibodies were removed, the samples were
inoculated with FCV at a multiplicity of infection of 0.01 and
incubated for 1 h at 37 °C. The cytopathic effect (CPE) was mon-
itored at 24 hpi by evaluating cell morphology using a phase-
contrast microscope. For competition experiments, FL rNCL or BSA
(120 nM each) were incubated with FCV (MOI¼ 0.01) for 3 h, at
RT, and protein pre-incubated viruses were added to 80% con-
ﬂuent CrFK cells monolayers in 96-well plates and kept them at
37 °C for 1 h. After removal of unbounded viruses, cells were kept
for an additional 24 h at 37 °C. Supernatants were collected and
virus titration was performed by plaque assay. For competition
experiments using the NCL ligand FITC-AGRO, 5105 cells were
incubated 45 min on ice with a mix of 1 μM FL rNCL or rGST
proteins pre-incubated with 5 μM FITC-AGRO for 2 h at 4 °C. The
samples were analyzed with a FACS Calibur (Becton Dickinson,
Franklin Lakes, MN).
Cloning, expression, and puriﬁcation of the recombinant ΔrNCL
protein
DNA fragment corresponding to amino acids 301-710 from the
human NCL (ΔrNCL) was ampliﬁed from HeLa cells (ATCC, Rock-
ville, MD) cDNA, by using Pfu DNA polymerase (Thermo Fisher
Scientiﬁc) and pair of primers: FW50-ACCATGGAATTCACA-
GAACCGACTACGGCTTTC-30, and RV50-GCCTTTCTCGAGCTATT-
CAAACTTCGTCTTCTTTCC-30. The sequences of primers included
EcoRI and XhoI recognition sites (underlined). The amplicon was
cloned into the cloning vector pJET1.2 (Thermo Scientiﬁc), and
sub-cloned into the EcoRI and XhoI enzyme sites of the prokar-
yotic expression vector pGEX5X.1. The resulting plasmid was
named pGEX5X.1-ΔrNCL and contained a truncated version of the
NCL gene. To express ΔrNCL, Escherichia coli BL21 cells were
transformed with pGEX5X.1-ΔrNCL, transformed cells were
grown to A600 and protein expression was induced by 0.1 mM IPTG
for 4 h at 37 °C. Recombinant protein puriﬁcation was performed
as follows: the cells were pelleted by centrifugation (JA-10 Beck-
man Coulter 30 min at 11,435g) and resuspended in a lysis buffer
that contained PBS-TritonX-100 1%, lysozyme (100 mg/ml) and
protease inhibitor (Complete Mini, Roche). The cells were incu-
bated 30 min at 4 °C and then sonicated. After the lysate was
centrifuged (JA-20 Beckman Coulter 30 min at 17,250g), the
supernatant was incubated with glutathione-agarose (G4510
Sigma-Aldrich) for 1 h, at 4 °C, the beads were washed three times
with PBS-Triton X100-1% and the bound protein was eluted with
500 μl of elution buffer (10 mM L-glutathione reduced G4251
(Sigma-Aldrich), 15 mM Tris–HCl pH 8.0). The eluted protein was
dialyzed against buffer containing 20 mM MOPS pH 7.2, 10 mM
NaCl, 50 mM KCl, 1.1 mM MgCl2, 0.1 mM EDTA, 0.5 mM dithio-
threitol (DTT). The puriﬁed ΔrNCL was stored at 80 °C.
For the expression of GFP-ΔrNCL in CrFK cells, the amplicon
corresponding to amino acids 301-710 from the human NCL
(ΔrNCL), was ampliﬁed from HeLa cells cDNA by using Pfu DNA
polymerase (Thermo Fisher Scientiﬁc) and a pair of primers with
B.A. Hernández et al. / Virology 489 (2016) 51–62 61EcoRI and ApaI sites (underlined): FW50- ACCATGGAATTCTACA-
GAACCGACTACGGCTTTC-30, and RV50- GCCTTTGGGCCCCTATT-
CAAACTTCGTCTTCTTTCC. The amplicon was cloned into the clon-
ing vector pJET1.2, and subcloned into the EcoRI and ApaI enzyme
sites of the eukaryotic expression vector pEGFP-C1. The resulting
plasmid was named pEGFP-C1-ΔrNCL and contained a truncated
version of the NCL gene under control of cytomegalovirus (CMV)
promoter. All plasmids containing the NCL amplicons were
sequenced to verify the inserts.Stable transfection of GFP-ΔrNCL into CrFK cells
Transfections of CrFK cells with 1 μg of pEGFP-C1 (Clontech
laboratories, Inc.) or pEGFP-C1-ΔrNCL plasmids were performed
by electroporation using Nucleofector™ Technology (T-020). For
stable transfection, the electroporated cells were selected using
growth medium that contained 2.5 mg/ml G418 (Sigma-Aldrich).
Stably transfected cells were maintained as populations in the
presence of 0.5 mg/mL G418.In vitro transcription assays
Two amplicons that corresponded to the 50 terminal region (TR)
(nts 1 to 182) and the complete 30UTR (nts 7646–7690) from the
FCV genomic RNA were obtained by PCR from FCV-infected CrFK
cells cDNA (M-MLV Reverse Transcriptase, Invitrogene) using a
sense primer that contained the bacteriophage T7 promoter
sequence (50RT-FW 50 -TAATACGACTCACTATAGGGGTAAAA-
GAAATTTGAGAC-30, 50RT-RV50-CATTGTCGAAGACCCGTC-30) and
(30UTR-FW-50 TAATACGACTCACTATAGGGTCATATATCCCTTTGGG,
3’UTR-RV-50 CCCTGGGGTTAGGCGCAGG-30). The PCR reactions
were performed with a Pfu DNA Polymerase (Thermo Fisher Sci-
entiﬁc) at 94 °C for 3 min, followed by 35 cycles of 94 °C for 30 s,
50 °C for 30 s, and 72 °C for 30 s, using a Perkin-Elmer Cetus DNA
thermocycler. RNA transcripts corresponding to the 50TR and
30UTR FCV regions were synthesized from the puriﬁed amplicons
using In vitroMEGAscripts T7 Transcription Kit (Life Technologies)
according to the manufacturer0s protocol. Following the synthesis,
the reaction mixtures were treated with DNAse 1 at 37 °C for
30 min to remove the template DNAs. Unincorporated nts were
removed by phenol:chloroform extraction and isopropanol pre-
cipitation. For the synthesis of radiolabeled transcripts, [α32P]-UTP
(Perkin Elmer) was included in the transcription reaction mixture.Electrophoretic mobility shift assays (EMSA)
EMSA was performed using a method described previously
(Cancio-Lonches et al., 2011). Brieﬂy, increasing concentrations of
ΔrNCL were pre-incubated for 15 min at 4 °C with the same
amount of tRNA in a buffer containing 10 mM HEPES (pH 7.4),
0.1 mM EDTA, 0.2 mM DTT, 8 mM MgCl2 and 10% (v/v) glycerol in
a ﬁnal volume of 15 μl. The reaction mixture was incubated for
30 min at 4 °C. The [α32P]-UTP-labeled (4105 cpm) RNA tran-
scripts corresponding to the FCV 50TR and 30UTR were added to
each reaction mixture and incubated for 15 min at 4 °C. Then, the
samples were incubated with 20 units of RNase A and 20 μg of
RNase T1 for 15 min at RT before loading the gels. The RNA–pro-
tein complexes were analyzed in a 4% (50 TR) and 8% (30UTR) native
gels. The gels were dried and autoradiographed. For EMSA per-
formed with FITC-labeled-AGRO-100 (Sigma-Aldrich), the com-
plexes were observed in a ChemidocTM MP Imagine system with
Image lab software (Bio-Rad).In vitro translation assays
FCV VPg-linked RNA was puriﬁed from FCV-infected (MOI¼40)
CrFK cells at 8 hpi. In vitro translation assays were performed in
Flexi rabbit reticulocyte lysates (RRLs, Promega). Each 12.5 μl
translation reaction included 6.25 μl of RRL, 20 μM amino acid
mixture minus methionine, 100 mM KCl, 2 mM DTT, 0.5 mM
MgOAc, 5 μCi35S methionine (1000 Ci/mmol) (GE Healthcare) and
400 ng of FCV VPg-linked RNA. The reactions were incubated at
30 °C for 1.5 h. The gels were dried and autoradiographed. Differ-
ent amounts of ΔrNCL, FL rNCL (OriGene) dialyzed in (20 mM
MOPS pH 7.2, 10 mM NaCl, 50 mM KCl, 1.1 mM MgCl2, 0.1 mM
EDTA, 0.5 mM DTT) and AGRO100 (Sigma-Aldrich) were added
into translation reactions as indicated. When FL rNCL was used,
the translation reaction was performed in a ﬁnal volume of 37 μl.
[35S]-methionine experiments
CrFK cells (1.25105), expressing GFP or GFP-ΔrNCL were
incubated with methionine-free MEM for 1 h, at 37 °C, and pulsed
with 50 μCi/ml)of [35S]-methionine for 1 h at 37 °C. Cells were
solubilized with SDS-PAGE sample buffer, and subjected to SDS-
PAGE and autoradiography.Acknowledgments
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